Presentation is loading. Please wait.

Presentation is loading. Please wait.

Securing the cure in resectable lung cancer

Published byWarren Martin Modified over 6 years ago

Similar presentations

Presentation on theme: "Securing the cure in resectable lung cancer"— Presentation transcript:

1 Securing the cure in resectable lung cancer
Presented By Suresh Senan at 2017 ASCO Annual Meeting

2 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Disclosures Presented By Suresh Senan at 2017 ASCO Annual Meeting

3 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Resectable NSCLC Presented By Suresh Senan at 2017 ASCO Annual Meeting

4 Treatment of stage I NSCLC: NCDB1
Presented By Suresh Senan at 2017 ASCO Annual Meeting

5 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Treatment of stage III NSCLC (TNM7) <br />Patterns of care in the Netherlands Cancer Registry1,2 Presented By Suresh Senan at 2017 ASCO Annual Meeting

6 Adjuvant therapy in resected NSCLC1
Presented By Suresh Senan at 2017 ASCO Annual Meeting

7 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Slide 7 Presented By Suresh Senan at 2017 ASCO Annual Meeting

8 EGFR mutated NSCLC: adjuvant
Presented By Suresh Senan at 2017 ASCO Annual Meeting

9 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Abstracts Presented By Suresh Senan at 2017 ASCO Annual Meeting

10 ADJUVANT study design (NCT01405079)
Presented By Suresh Senan at 2017 ASCO Annual Meeting

11 ADJUVANT Primary endpoint: DFS
Presented By Suresh Senan at 2017 ASCO Annual Meeting

12 ADJUVANT: Demographics (ITT population)
Presented By Suresh Senan at 2017 ASCO Annual Meeting

13 ADJUVANT trial: Comments
Presented By Suresh Senan at 2017 ASCO Annual Meeting

14 EGFR TKI Adjuvant Trials (in EGFRmut populations)
Presented By Suresh Senan at 2017 ASCO Annual Meeting

15 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Abstracts Presented By Suresh Senan at 2017 ASCO Annual Meeting

16 Management of Isolated Local-Regional Failure after SABR
Presented By Suresh Senan at 2017 ASCO Annual Meeting

17 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Post SABR follow-up Presented By Suresh Senan at 2017 ASCO Annual Meeting

18 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Slide 18 Presented By Suresh Senan at 2017 ASCO Annual Meeting

19 Post SABR salvage treatments
Presented By Suresh Senan at 2017 ASCO Annual Meeting

20 SABR: Actuarial Patterns of Failure
Presented By Suresh Senan at 2017 ASCO Annual Meeting

21 Post-SABR isolated recurrences
Presented By Suresh Senan at 2017 ASCO Annual Meeting

22 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Slide 22 Presented By Suresh Senan at 2017 ASCO Annual Meeting

23 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Abstracts Presented By Suresh Senan at 2017 ASCO Annual Meeting

24 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Slide 24 Presented By Suresh Senan at 2017 ASCO Annual Meeting

25 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Overall survival Presented By Suresh Senan at 2017 ASCO Annual Meeting

26 Presented By Suresh Senan at 2017 ASCO Annual Meeting
NVALT 11: Endpoints Presented By Suresh Senan at 2017 ASCO Annual Meeting

27 Presented By Suresh Senan at 2017 ASCO Annual Meeting
<br />NVALT 11 (Primary endpoint) : Brain metastases (BM) and neurological symptoms Presented By Suresh Senan at 2017 ASCO Annual Meeting

28 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Slide 28 Presented By Suresh Senan at 2017 ASCO Annual Meeting

29 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Slide 29 Presented By Suresh Senan at 2017 ASCO Annual Meeting

30 Presented By Suresh Senan at 2017 ASCO Annual Meeting
Conclusions Presented By Suresh Senan at 2017 ASCO Annual Meeting

Download ppt "Securing the cure in resectable lung cancer"

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
James R. Rigas Comprehensive Thoracic Oncology Program

James R. Rigas Comprehensive Thoracic Oncology Program
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Www.OncologyEducation.ca Randomized Trial of p53 Targeted Adjuvant Therapy for Patients (pts) With Organ-Confined Node-Negative Urothelial Bladder Cancer.

Randomized Trial of p53 Targeted Adjuvant Therapy for Patients (pts) With Organ-Confined Node-Negative Urothelial Bladder Cancer.
A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor Gefitinb in Completely Resected Stage.

A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor Gefitinb in Completely Resected Stage.
Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.
Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting
Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.

Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.

Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.
Network Experience of TKI inhibitors as 1 st line use in advanced NSCLC Dr Jill Gardiner and Mr Steve Williamson April 2012.

Network Experience of TKI inhibitors as 1 st line use in advanced NSCLC Dr Jill Gardiner and Mr Steve Williamson April 2012.
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.

Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.
First-Line TKI Use in EGFR Mutation-Positive NSCLC

First-Line TKI Use in EGFR Mutation-Positive NSCLC
Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,

Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

Similar presentations

Ads by Google